A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.

Also called NCT01529528

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 117 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01529528
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01529528. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
Acronym
CWP-DIANA-301
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Anagliptin
Intervention (Drug)
Anagliptin
Intervention (Drug)
Placebo of Anagliptin
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01529528
Content hash
36655502086bdc77def1c9460ce49eed005934f4aa8d137e709ceca147d6c29d